Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Anika Therapeutics (ANIK) Accumulated Depreciation & Amortization (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Accumulated Depreciation & Amortization for 16 consecutive years, with $51.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 11.11% to $51.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $51.4 million, a 11.11% increase, with the full-year FY2025 number at $51.4 million, up 11.11% from a year prior.
  • Accumulated Depreciation & Amortization was $51.4 million for Q4 2025 at Anika Therapeutics, up from $50.6 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $51.4 million in Q4 2025 to a low of $35.2 million in Q4 2023.
  • A 5-year average of $44.9 million and a median of $46.2 million in 2022 define the central range for Accumulated Depreciation & Amortization.
  • Peak YoY movement for Accumulated Depreciation & Amortization: fell 23.71% in 2023, then surged 31.36% in 2024.
  • Anika Therapeutics' Accumulated Depreciation & Amortization stood at $39.6 million in 2021, then rose by 16.67% to $46.2 million in 2022, then dropped by 23.71% to $35.2 million in 2023, then soared by 31.36% to $46.3 million in 2024, then rose by 11.11% to $51.4 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Accumulated Depreciation & Amortization are $51.4 million (Q4 2025), $50.6 million (Q2 2025), and $46.3 million (Q4 2024).